VTVT Stock — vTv Therapeutics Inc.: Cash, EV, Pipeline

Share price

$31.80

Market cap

$125.7M

Cash

$86.6M

Enterprise value

$39.1M

Balance sheet

Cash	$86.6M
Debt	$0.0M
Net cash	$86.6M
Enterprise value	$39.1M
Basic shares	3.9M shares
Fully diluted shares	10.7M shares
Fully diluted market cap	$341.0M
Cash per share	$21.99

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading VTVT daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
May 13 - Jun 24	Cadisegliatin 800 mg QD	Phase 3	Diabetes Mellitus, Type 1	—
May 13 - Jun 24	Cadisegliatin 800 mg QD	Phase 2	Type 1 Diabetes (T1D)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

cadisegliatin

Phase 3 · Active Modality: small molecule (oral)

Aliases TTP399

Target glucokinase

Partnerships G42 Healthcare Research Technology Projects LLC (collaboration and license; joint development and commercialization of cadisegliatin in the Middle East, Africa and Central Asia; single-digit royalties); Novo Nordisk (worldwide exclusive license to GKA program; milestones plus mid-single-digit royalties)

Indications

Type 1 diabetes, adjunctive to insulin (Phase 3)
Type 2 diabetes (insulin-using patients) (Phase 2)

Catalysts

— third quarter of 2026
— late 2026

Status note Liver-selective glucokinase activator. FDA granted Breakthrough Therapy designation in 2021 for T1D adjunctive-to-insulin use. Phase 3 CATT1 trial resumed May 2025. Phase 2 trial in insulin-using T2D patients in the Middle East initiated December 2025 with G42. Additional registrational studies for T1D expected to start in 2027.

HPP737

Stage not disclosed · Active Modality: small molecule (oral)

Target PDE4

Partnerships Newsoara Biopharma Co., Ltd. (exclusive global license, Second Amendment January 2026; $20M upfront received February 2026; up to ~$50M development milestones, $65M sales milestones, mid-single-digit royalties)

Indications

Not disclosed (Stage not disclosed)

Status note Development and commercialization handled by Newsoara under expanded global rights (Second Amendment, January 2026; upfront fee received February 2026).

azeliragon

Stage not disclosed · Active Modality: small molecule (oral)

Target RAGE (receptor for advanced glycation end-products)

Partnerships Cantex Pharmaceuticals, Inc. (exclusive worldwide license, June 2021; Cantex responsible for development and commercialization; tiered downstream profit arrangement)

Indications

Not disclosed (Stage not disclosed)

Status note Cantex holds exclusive worldwide rights to develop and commercialize azeliragon, vTv's novel RAGE antagonist.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Cadisegliatin 800 mg QD
Lead indication	Diabetes Mellitus, Type 1
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06334133	Phase 3	Active, not recruiting	Sponsor	vTv Therapeutics	—	Diabetes Mellitus, Type 1	—
NCT07616206	Phase 2	Not yet recruiting	Sponsor	vTv Therapeutics	—	Type 1 Diabetes (T1D)	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for vTv Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	148,314	no change	0.03%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

VTVT — vTv Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders